New Phase 3 trial: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight — Amgen

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-13 12:00 UTC

KINDCompany

DIRECTION■ Mixed

SOURCES1

ENTITIES1

STORY SIZESTANDALONE

FIRST SEEN2026-10-13 12:00 UTC

LAST UPDATE2026-10-13 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Amgen obesity drug self-administration trial signals competitive push in a hot market.

Amgen tests obesity drug autoinjector

CATALYST TO WATCH

Trial enrollment and data timing

MAIN RISK

Competitive obesity field is crowded

FULL DISPATCH

Sponsor: Amgen; Status: Not Yet Recruiting; Conditions: Obesity, Overweight; Interventions: Maridebart cafraglutide, Autoinjector; Enrollment: 230 (estimated); First posted: 2026-10-13; NCT: NCT07871409

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-13 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←INFERENCEfilings generate company commentary
JPM filed 8-K on 2026-10-132026-10-13 00:00 UTC

←INFERENCEfilings generate company commentary
UNH filed 8-K on 2026-10-132026-10-13 00:00 UTC

←INFERENCEfilings generate company commentary
GS filed 8-K on 2026-10-132026-10-13 00:00 UTC

←INFERENCEfilings generate company commentary
JNJ filed 8-K on 2026-10-132026-10-13 00:00 UTC

←CORRELATIONshares Healthcare
Semaglutide-treated aged mice lost late-life lean mass. Pulmatrix (PULM) shares a PTC-2105 comparison.2026-10-13 11:12 UTC

←CORRELATIONshares Healthcare
Vector Science and Therapeutics Corp. Announces Collaboration and SAFE Investment in Whoopi Wellness, Inc.2026-10-13 11:30 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.